BACKGROUND: The prognosis for hepatobiliary and pancreatic malignancies is dismal. Surgery remains the primary curative option, but unresectable disease is often discovered during operative exploration. Positron emission tomography (PET) provides unique biological information different from current imaging modalities. The role of PET in detecting hepatobiliary and pancreatic malignancies has not yet been established. The purpose of this article was to review the literature on the use of PET in hepatobiliary and pancreatic malignancies. DATA SOURCES: We performed an extensive search on PubMed using PET and hepatocellular, pancreatic, gallbladder, and cholangiocarcinoma as keywords, excluding articles not written in English or on nonhuman subjects, case reports, and series with <5 patients. CONCLUSIONS: Although PET has shown usefulness in the diagnosis of certain cancers, current literature cautions against the use of PET for determining malignant potential of primary liver and pancreatic lesions. Literature on PET more strongly supports clinical roles for restaging of hepatobiliary and pancreatic malignancies, and for identifying metastatic disease.
BACKGROUND: The prognosis for hepatobiliary and pancreatic malignancies is dismal. Surgery remains the primary curative option, but unresectable disease is often discovered during operative exploration. Positron emission tomography (PET) provides unique biological information different from current imaging modalities. The role of PET in detecting hepatobiliary and pancreatic malignancies has not yet been established. The purpose of this article was to review the literature on the use of PET in hepatobiliary and pancreatic malignancies. DATA SOURCES: We performed an extensive search on PubMed using PET and hepatocellular, pancreatic, gallbladder, and cholangiocarcinoma as keywords, excluding articles not written in English or on nonhuman subjects, case reports, and series with <5 patients. CONCLUSIONS: Although PET has shown usefulness in the diagnosis of certain cancers, current literature cautions against the use of PET for determining malignant potential of primary liver and pancreatic lesions. Literature on PET more strongly supports clinical roles for restaging of hepatobiliary and pancreatic malignancies, and for identifying metastatic disease.
Authors: M A Khan; C S Combs; E M Brunt; V J Lowe; M K Wolverson; H Solomon; B T Collins; A M Di Bisceglie Journal: J Hepatol Date: 2000-05 Impact factor: 25.083
Authors: L James Wudel; Dominique Delbeke; David Morris; Michael Rice; Mary Kay Washington; Yu Shyr; C Wright Pinson; William C Chapman Journal: Am Surg Date: 2003-02 Impact factor: 0.688
Authors: Antonio Rodríguez-Fernández; Manuel Gómez-Río; José Manuel Llamas-Elvira; Simeón Ortega-Lozano; Jose Antonio Ferrón-Orihuela; Jose Manuel Ramia-Angel; Alfonso Mansilla-Roselló; María Dolores Martínez-del-Valle; Carlos Ramos-Font Journal: Am J Surg Date: 2004-08 Impact factor: 2.565
Authors: Saila P Kauhanen; Gaber Komar; Marko P Seppänen; Kirsti I Dean; Heikki R Minn; Sami A Kajander; Irina Rinta-Kiikka; Kalle Alanen; Ronald J Borra; Pauli A Puolakkainen; Pirjo Nuutila; Jari T Ovaska Journal: Ann Surg Date: 2009-12 Impact factor: 12.969
Authors: Christopher D Anderson; Michael H Rice; C Wright Pinson; William C Chapman; Ravi S Chari; Dominique Delbeke Journal: J Gastrointest Surg Date: 2004-01 Impact factor: 3.452
Authors: Ana F Brito; Ana M Abrantes; Marina Ribeiro; Rui Oliveira; João Casalta-Lopes; Ana C Gonçalves; Ana B Sarmento-Ribeiro; José G Tralhão; Maria F Botelho Journal: J Clin Exp Hepatol Date: 2015-06-03
Authors: Sandi A Kwee; Miles M Sato; Yu Kuang; Adrian Franke; Laurie Custer; Kyle Miyazaki; Linda L Wong Journal: Mol Imaging Biol Date: 2017-06 Impact factor: 3.488
Authors: Reinier Hernandez; Haiyan Sun; Christopher G England; Hector F Valdovinos; Emily B Ehlerding; Todd E Barnhart; Yunan Yang; Weibo Cai Journal: Theranostics Date: 2016-08-08 Impact factor: 11.556